Development and optimization of high-throughput in vitro protein phosphatase screening assays

Area of Science:

• Biochemistry
• Enzymology
• Drug Discovery

Background:

• Dual-specificity phosphatases (DSPs) like CDC25B, MKP-1, and MKP-3 are critical regulators of cellular signaling pathways.
• Dysregulation of DSP activity is implicated in various diseases, making them attractive targets for therapeutic intervention.
• Developing robust high-throughput screening (HTS) assays is essential for identifying novel DSP inhibitors.

Purpose of the Study:

• To describe detailed protocols for designing, optimizing, and validating in vitro phosphatase assays.
• To adapt these assays for a miniaturized 384-well, high-throughput screening format.
• To ensure the developed assays meet stringent performance criteria for HTS.

Main Methods:

• Development and optimization of in vitro phosphatase assays for CDC25B, MKP-1, and MKP-3.
• Miniaturization of assays into a 384-well format.
• Validation of assay performance, including Z-factor and variability (CV).

Main Results:

• Protocols for designing, optimizing, and validating in vitro phosphatase assays are detailed.
• The assays were successfully miniaturized into a reproducible and cost-effective 384-well HTS format.
• Optimized assays demonstrated robust performance with Z-factors >0.5 and low variability (CV <20%).

Conclusions:

• The presented protocols enable the development of robust and validated in vitro phosphatase HTS assays.
• These assays are suitable for screening inhibitors of CDC25B, MKP-1, and MKP-3.
• A single investigator can establish a 384-well HTS assay within 3-4 weeks with appropriate resources.